BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

07 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

20 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in September Investor Events

06 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

18 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

10 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update

04 Aug 2022 07:30:01 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

26 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

25 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases

21 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub

21 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers

27 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

22 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

13 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations

10 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference

09 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in June Investor Events

06 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias

26 May 2022 13:00:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

20 May 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in May Investor Events

17 May 2022 07:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years

13 May 2022 07:30:00 By Nasdaq GlobeNewswire